Major depressive disorder (MDD) is a common illness accompanied by considerable morbidity, mortality, costs, and heightened risk of suicide. We conducted a genome-wide association meta-analysis based in 135,458 cases and 344,901 controls and identified 44 independent and significant loci. The genetic findings were associated with clinical features of major depression and implicated brain regions exhibiting anatomical differences in cases. Targets of antidepressant medications and genes involved in gene splicing were enriched for smaller association signal. We found important relationships of genetic risk for major depression with educational attainment, body mass, and schizophrenia: lower educational attainment and higher body mass were putatively causal, whereas major depression and schizophrenia reflected a partly shared biological etiology. All humans carry lesser or greater numbers of genetic risk factors for major depression. These findings help refine the basis of major depression and imply that a continuous measure of risk underlies the clinical phenotype.
M
DD is a notably complex and common illness 1 . It is often chronic or recurrent and is thus accompanied by considerable morbidity, disability, excess mortality, substantial costs, and heightened risk of suicide [2] [3] [4] [5] [6] [7] [8] . Twin studies attribute approximately 40% of the variation in liability to MDD to additive genetic effects (phenotype heritability, h 2 ) 9 , and h 2 may be greater for recurrent, early-onset, and postpartum MDD 10, 11 . Genome-wide association studies (GWAS) of MDD have had notable difficulties in identifying individual associated loci 12 . For example, there were no significant findings in the initial Psychiatric Genomics Consortium (PGC) MDD mega-analysis (9,240 cases) 13 or in the CHARGE meta-analysis of depressive symptoms (n = 34,549) 14 . More recent studies have proven modestly successful. A study of Han Chinese women (5,303 recurrent MDD cases) identified significant loci 15 , a meta-analysis of depressive symptoms (161,460 individuals) identified 2 loci 16 , and an analysis of self-reported major depression identified 15 loci (75,607 cases).
There are many reasons why identifying causal loci for MDD has proven difficult 12 . MDD is probably influenced by many genetic loci, each with small effects 17 , as are most common diseases 18 , including psychiatric disorders 19, 20 . Estimates of the proportion of variance attributable to genome-wide SNPs (SNP heritability, h SNP 2 ) indicate that around one-quarter of the h 2 for MDD is due to common genetic variants 21, 22 and demonstrate that a genetic signal is detectable in genome-wide association data, implying that larger sample sizes are needed to detect specific loci given their effect sizes. Such a strategy has been proven in studies of schizophrenia, the flagship adult psychiatric disorder in genomics research. We thus accumulated clinical, population, and volunteer cohorts 23 . This pragmatic approach takes the view that sample size can overcome heterogeneity to identify risk alleles that are robustly associated with major depression. Potential concerns about combining carefully curated research cohorts with volunteer cohorts were considered; multiple lines of evidence suggest that the results are likely to be applicable to clinical MDD. As discussed below, our analyses have neurobiological, clinical, and therapeutic relevance for major depression.
Results
Cohort analyses: phenotype validation. We identified seven cohorts that used a range of methods to ascertain cases with major depression (Table 1 and Supplementary Tables 1-3 ). The methods used by these cohorts were thoroughly reviewed, drawing on the breadth of expertise in the PGC, and we assessed the comparability of the cohorts using genomic data. We use 'MDD' to refer to directly evaluated subjects meeting standard criteria for major depressive disorder and use 'major depression' where case status was determined using alternative methods as well as to the phenotype from the full meta-analysis.
We evaluated the comparability of the seven cohorts by estimating the common variant genetic correlations (r g ) between them. These analyses supported the comparability of the seven cohorts (Supplementary Table 3) , as the weighted mean r g was 0.76 (s.e. = 0.03). The high genetic correlations between the 23andMe and other cohorts are notable. While there was no statistical evidence of heterogeneity in the r g estimates for pairs of cohorts (P = 0.13), the estimate was statistically different from 1, which may reflect etiological heterogeneity. This estimate can be benchmarked against the slightly larger weighted mean r g between schizophrenia cohorts of 0.84 (s.e. = 0.05) 21 . Given the positive evidence of the genetic comparability of these cohorts, we completed a genome-wide association meta-analysis of 9.6 million imputed SNPs in 135,458 MDD and major depression cases and 344,901 controls ( Fig. 1 ). There was no evidence of residual population stratification 24 (LD score regression intercept = 1.018, s.e. = 0.009). We estimated h SNP 2 to be 8.7% (s.e. = 0.004, liability scale, assuming lifetime risk of 0.15; Supplementary Fig. 1 and Supplementary Table 3b), and note that this is about onequarter of the h 2 estimated from twin or family studies 9 . This fraction is somewhat lower than that of other complex traits 18 and is plausibly due to etiological heterogeneity (reflecting the mean r g < 1 between cohorts).
To evaluate the impact of combining major depression cohorts that used different ascertainment methods, we undertook a series of genetic risk score (GRS) prediction analyses to demonstrate the validity of our genome-wide association results for clinical MDD (Fig. 2) . Notably, the variance explained in out-of-sample prediction increased with the size of the genome-wide association discovery cohort (Fig. 2a) , with the GRS from the full discovery
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sample meta-analysis explaining 1.9% of variance in liability (Fig. 2a, Supplementary Fig. 2 , and Supplementary Table 4) . For any randomly selected case and control, GRS ranked cases higher than controls with probability of 0.57 and the odds ratio of MDD for those in the tenth versus first GRS decile (OR = 10) was 2.4 ( Fig. 2b and Supplementary Table 4) . GRS analyses in other disorders (for example, schizophrenia 25 ) have shown that the mean GRS increases with clinical severity in cases. We found a significantly higher major depression GRS in those with more severe MDD, as measured in different ways (Fig. 2c) . Last, because around one-half of the major depression cases were identified by self-report (i.e., diagnosis or treatment for clinical depression by a medical professional), we further evaluated the comparability of the 23andMe cohort with the other cohorts (full meta-analysis excluding 23andMe, 'FMex23andMe') as detailed in Fig. 2c , Supplementary Table 5 , and the Supplementary Note. Taken together, we interpret these results as supporting this meta-analysis of GWAS for these seven cohorts.
Implications for the biology of major depression. Our metaanalysis of seven MDD and major depression cohorts identified 44 independent loci that were statistically significant (P < 5 × 10 −8
), statistically independent of any other signal 26 , and supported by multiple SNPs. This number supports our prediction that genome-wide association discovery in major depression would require about five times more cases than for schizophrenia (lifetime risk ~1% and h 2 ~0.8) to achieve approximately similar power 27 . Of these 44 loci, 30 are new and 14 were significant in a prior study of MDD or depressive symptoms. The overlap of our findings with prior reports was as follows: 1 of 1 with CHARGE depressive symptom 14 , 1 of 2 overlap with SSGAC depressive symptom 16 , and 12 of 15 overlap with Hyde et al. 28 . There are few trans-ancestry comparisons for major depression, so we contrasted these European results with the Han Chinese CONVERGE study 15 (Supplementary Note). The loci identified in CONVERGE are uncommon in Europeans (rs12415800, 0.45 versus 0.02; rs35936514, 0.28 versus 0.06) and were not significant in our analysis. Table 2 lists genes in or near the lead SNP in each region, regional plots are in Supplementary Data 1, and Supplementary Tables 6  and 7 provide summaries of available information about the biological functions of the genes in each region. In the Supplementary Note, we review four key genes in more detail: OLFM4 and NEGR1 (notable for reported associations with obesity and body mass index [29] [30] [31] [32] [33] [34] ), RBFOX1 (notable for independent associations at both the 5′ and 3′ ends, a splicing regulator 35, 36 , with a functional role that may be consistent with chronic hypothalamic-pituitary-adrenal axis hyperactivation reported in MDD 37 ), and LRFN5 (notable for its role in presynaptic differentiation 38, 39 and neuroinflammation 40 ). Gene-wise analyses identified 153 significant genes after controlling for multiple comparisons (Supplementary Table 7) . Many of these genes were in the extended major histocompatibility complex (MHC) region (45 of 153), and their interpretation is complicated by high linkage disequilibrium (LD) and gene density. In addition to the genes discussed above, other notable and significant genes outside of the MHC region include multiple potentially 'druggable' targets that suggest connections of the pathophysiology of MDD to neuronal calcium signaling (CACNA1E and CACNA2D1), dopaminergic neurotransmission (DRD2, a principal target of antipsychotics), glutamate neurotransmission (GRIK5 and GRM5), and presynaptic vesicle trafficking (PCLO).
Finally, comparison of the major depression loci with 108 loci for schizophrenia 19 identified 6 shared loci. Many SNPs in the extended MHC region are strongly associated with schizophrenia, but implication of the MHC region is new for major depression. Another example is TCF4 (transcription factor 4), which is strongly associated with schizophrenia but was not previously associated with MDD. TCF4 is essential for normal brain development, and rare mutations in TCF4 cause Pitt-Hopkins syndrome, which includes autistic features 41 . The GRS calculated from the schizophrenia Expected -log 10 (P)   18   15   12   9   6   3   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17 18  19  20 ). c, Manhattan plot for association tests from meta-analysis of 135,458 major depression cases and 344,901 controls, with the x axis showing genomic position (chromosomes 1-22 plus the X chromosome) and the y axis showing statistical significance as -log 10 (P) z statistics; the threshold for significance accounting for multiple testing is shown by the red horizontal line (P = 5 × 10 −8 ).
Implications from integration of functional genomic data.
Results from 'omic' studies of functional features of cells and tissues are necessary to understand the biological implications of the results of GWAS for complex disorders 42 . To further elucidate the biological relevance of the major depression findings, we integrated the results with functional genomic data. First, using enrichment analyses, we compared the major depression GWAS findings to bulk tissue mRNA-seq from Genotype-Tissue Expression (GTEx) data 43 . Only brain samples showed significant enrichment (Fig. 3a) , and the three tissues with the most significant enrichments were all cortical. Prefrontal cortex and anterior cingulate cortex are important for higher-level executive functions and emotional regulation, which are often impaired in MDD. Both of these regions were implicated in a large meta-analysis of brain magnetic resonance imaging (MRI) findings in adult MDD cases 44 . Second, given the predominance of neurons in the cortex, we confirmed that the major depression genetic findings connect to genes expressed in neurons but not oligodendrocytes or astrocytes (Fig. 3b) 
45
. Given the different methods used by the seven MDD/major depression cohorts in this study, demonstration of enrichment of association signals in the brain regions expected to be most relevant to MDD provides independent support for the validity of our approach.
Third, we used partitioned LD score regression 46 to evaluate the enrichment of the major depression genome-wide association findings in over 50 functional genomic annotations ( Fig. 3c and Supplementary Table 8 ). This annotation was also the most enriched for schizophrenia 46 . We could not evaluate regions conserved in primates or human 'accelerated' regions, as there were too few for confident evaluation 47 . The other enrichments implied regulatory activity and included open chromatin in human brain and an epigenetic mark of active enhancers (H3K4me1). Notably, exonic regions did not show enrichment, suggesting that, as with schizophrenia 17 , genetic variants that change exonic sequences may not have a large role in major depression. We found no evidence that Neanderthal introgressed regions were enriched for major depression genome-wide association findings 48 . Fourth, we applied methods to integrate genome-wide association SNP results with those from gene expression and methylation quantitative trait locus (eQTL and meQTL) studies. SMR 49 analysis identified 13 major depression-associated SNPs with strong evidence that they control local gene expression in one or more tissues and 9 with strong evidence that they control local DNA methylation (Supplementary Table 9 and Supplementary Data 2). A transcriptome-wide association study 50 applied to data from the dorsolateral prefrontal cortex 51 identified 17 genes where major depressionassociated SNPs influenced gene expression (Supplementary Table 10 ). These genes included OLFM4 (discussed above).
Fifth, we added additional data types to attempt to improve understanding of individual loci. For the intergenic associations, we evaluated total-stranded RNA-seq data from human brain and found no evidence for unannotated transcripts in these regions. A particularly important data type is assessment of DNA-DNA interactions, which can localize a genome-wide association finding to a specific gene that may be nearby or hundreds of kilobases away [52] [53] [54] . We integrated the major depression results with 'easy Hi-C' data from brain cortical samples (3 adult, 3 fetal, > 1 billion reads each). These data clarified three associations. The statistically independent associations in NEGR1 (rs1432639, P = 4.6 × 10 −15 ) and over 200 kb away (rs12129573, P = 4.0 × 10 −12 ) both implicate NEGR1 ( Supplementary Fig. 3a ), the former likely due to the presence of a reportedly functional copy number polymorphism (see Supplementary Note) and the presence of intergenic loops. The latter association has evidence of DNA looping interactions with NEGR1. The association in SOX5 (rs4074723) and the two statistically independent associations in RBFOX1 (rs8063603 and rs7198928, P = 6.9 × 10 −9 and 1.0 × 10 −8 ) had only intragenic associations, suggesting that the genetic variation in the regions of the major depression associations act locally and can be assigned to these genes. In contrast, the association in RERE (rs159963, P = 3.2 × 10 −8 ) could not be assigned to RERE as it may contain super-enhancer elements given its many DNA-DNA interactions with many nearby genes ( Supplementary Fig. 3b ).
Implications based on the roles of sets of genes. A parsimonious explanation for the presence of many significant associations for a complex trait is that the different associations are part of a higherorder grouping of genes 55 . These could be a biological pathway or a collection of genes with a functional connection. Multiple methods allow evaluation of the connection of major depression genomewide association results to sets of genes grouped by empirical or predicted function (pathway or gene set analysis).
Full pathway analyses are in Supplementary Table 11 , and 19 pathways with false discovery rate q values < 0.05 are summarized in Fig. 4 . The major groupings of significant pathways were as follows: RBFOX1, RBFOX2, RBFOX3, or CELF4 regulatory networks; genes whose mRNAs are bound by FMRP; synaptic genes; genes Nineteen samples in addition to the ten samples published in the first PGC-MDD paper 13 . b One sample used natural language processing of electronic medical records followed by expert diagnostic review. In Hyde et al. 28 , SNPs in 15 genomic regions met genome-wide significance in the combined discovery and replication samples and 11 regions achieved genome-wide significance in the discovery sample made available to the research community and used here. More details are provided in Supplementary Tables 1-3 .
involved in neuronal morphogenesis; genes involved in neuron projection; genes associated with schizophrenia (at P < 10
; genes involved in central nervous system (CNS) neuron differentiation; genes encoding voltage-gated calcium channels; genes involved in cytokine and immune response; and genes known to bind to the retinoid X receptor. Several of these pathways are implicated by GWAS of schizophrenia and by rare exonic variation of schizophrenia and autism 56, 57 and immediately suggest shared biological mechanisms across these disorders.
A key issue for common variant GWAS is their relevance for pharmacotherapy. We conducted gene set analysis that compared the major depression genome-wide association results to targets of antidepressant medications defined by pharmacological studies 58 and found that 42 sets of genes encoding proteins bound by antidepressant medications were highly enriched for smaller major depression association P values than expected by chance (42 drugs, rank enrichment test P = 8.5 × 10
−10
). This finding connects our major depression genomic findings to MDD therapeutics and suggests the salience of these results for new lead compound discovery for MDD 59 .
Implications based on relationships with other traits. Prior epidemiological studies associated MDD with many other diseases and traits. Because of limitations inherent to observational studies, understanding whether a phenotypic correlation is potentially causal or if it results from reverse causation or confounding is generally difficult. Genetic studies now offer complementary strategies to assess whether a phenotypic association between MDD and a risk factor or a comorbidity is mirrored by a nonzero r g (common variant genetic correlation) and, for some of these, evaluate the potential causality of the association given that exposure to genetic risk factors begins at conception.
We used LD score regression to estimate the r g of major depression with 221 psychiatric disorders, medical diseases, and human traits 22, 60 . Supplementary Table 12 contains the full results, and Table 3 shows the r g values with false discovery rates < 0.01. First, the r g values were very high between our major depression genomewide association results and those from two studies of current depressive symptoms. Both correlations were close to 1 (the samples in one report overlapped partially with this meta-analysis 16 , but the samples from the other did not 14 ). Second, we found significant positive genetic correlations between major depression and every psychiatric disorder assessed along with smoking initiation. This is a comprehensive and wellpowered evaluation of the relationship of MDD with other psychiatric disorders, and these results indicate that the common genetic 77 . Error bars represent 95% confidence intervals. Logistic regression association test P values are shown in the target sample for the GRS generated from SNPs with P < 0.05 in the discovery sample. FMex23andMe, full meta-analysis excluding 23andMe; scz, schizophrenia 19 . variants that predispose to MDD overlap substantially with those for adult-and childhood-onset psychiatric disorders, although they remain substantially distinct as well. Third, the common variant genetic architecture of major depression was positively correlated with multiple measures of sleep quality (daytime sleepiness, insomnia, and tiredness). The first two of these correlations used UK Biobank data with people endorsing major depression or other major psychiatric disorders, shift workers, and those taking hypnotics excluded. This pattern of correlations combined with the importance of sleep and fatigue in major depression (two criteria for MDD) suggests a close and potentially profound mechanistic relationship. Major depression also had a strong genetic correlation with neuroticism (a personality dimension assessing the degree of emotional instability); this is consistent with the literature showing a close interconnection of MDD and this personality trait. The strong negative r g with subjective well-being underscores the capacity of major depression to impact human health.
Finally, major depression had significant negative genetic correlations with data from two studies of educational attainment, which while often considered at the genetic level as proxy measures of intelligence also likely includes more complex personality constructs. With this in mind, it is relevant to note that the r g between major depression and IQ 61 was not significantly different from zero, despite the r g between years of education and IQ being 0.7, implying complex relationships between these traits worthy of future investigation. We also found significant positive correlations with multiple measures of adiposity, relationship to female reproductive behavior (decreased age at menarche, age at first birth, and increased number of children), and positive correlations with coronary artery disease and lung cancer.
We used bidirectional Mendelian randomization (MR) to investigate the relationships between four traits genetically correlated with major depression: years of education (EDY) 62 , body mass index (BMI) 29 , coronary artery disease (CAD) 63 , and schizophrenia 19 . These traits were selected because all of the following were true: they were phenotypically associated with MDD, had significant r g with MDD, and had > 30 independent genome-wide significant associations from large GWAS. We report GSMR 64 results but obtained qualitatively similar results with other MR methods ( Supplementary Fig. 4 and Supplementary ) and a 0.84-fold decrease in major depression per s.d. of EDY (P GSMR = 2.3 × 10
−6
). There was no evidence of reverse causality of major depression for BMI (P GSMR = 0.53) or EDY (P GSMR = 0.11). For BMI, there was some evidence of pleiotropy, as six BMI-associated SNPs were excluded by the HEIDI outlier test including SNPs near OLFM4 and NEGR1. Thus, these results are consistent with EDY and BMI as either causal risk factors or correlated with causal risk factors for major depression. These results provide hypotheses for future research to understand these potentially directional relationships.
For CAD, the MR analyses were not significant when considering major depression as an outcome (P GSMR = 0.30) or as an exposure (P GSMR = 0.12); however, the high standard error of the estimates using MDD SNP instruments implies that this analysis should be revisited when more major genome-wide significant SNP instruments for depression become available from future GWAS.
We used MR to investigate the relationship between major depression and schizophrenia. Although major depression had positive r g with many psychiatric disorders, only schizophrenia had Chr. (chromosome) and region (boundaries in Mb; hg19) are shown, defined by the locations of SNPs with P < 1 × 10 −5 and LD r 2 > 0.1 with the most strongly associated SNP (logistic regression; the lowest P value in the region listed is not corrected for multiple testing), whose location is given in base pairs. In three regions, a second SNP fulfilled the filtering criteria and was followed up with conditional analyses: chr. 1, conditional analysis selected only rs1432639 as significant, with P = 2.0 × 10 −4 for rs12134600 after fitting rs1432639; chr. 5, conditional analysis showed two independent associations selecting rs247910 and rs10514301 as the most strongly associated SNPs; chr. 10, conditional analysis selected only rs61867293 with P = 8.6 × 10 −5 for rs1021363 after conditioning on rs61867293.
For each of the 47 SNPs, there was at least one additional genome-wide significant SNP in the cluster of surrounding SNPs with low P values. Chromosome X was analyzed but had no findings that met genome-wide significance. Entries in the "Prev." column indicate which of four previous studies identified genome-wide significant associations in a region: H, Hyde et al. 28 , 23andMe genome-wide association of self-reported clinical depression (the discovery sample overlaps with this paper); O, Okbay et al. 16 , meta-analysis of genome-wide association of MDD, depressive symptoms, psychological well-being, and neuroticism (includes many PGC29 samples); S, PGC report on 108 schizophrenia-associated loci 19 ; C, CHARGE Consortium meta-analysis of depressive symptoms 14 . The "Gene context" column shows the distances between the peak SNP and the closest genes; brackets indicate that the peak SNP was within that gene. The closest genes upstream (taking strand into account; a negative number indicates distance in base pairs between the peak SNP and the nearest gene boundary) and downstream (positive distance in base pairs) are also shown if there was a flanking gene within 200 kb. The name of the closest gene is in brackets. Note that it is generally not known whether associated SNPs have biological effects on these or other more distant genes. A1/A2, the two alleles (or insertiondeletion) at each SNP; A1 was tested for association and its OR (odds ratio) and s.e. are shown; Freq., the frequency of A1 in controls across all cohorts.
Table 2 | 44 significantly associated genomic regions in meta-analysis of 135,458 major depression cases and 344,901 controls (continued)
sufficient associations for MR analyses. We found significant bidirectional correlations in SNP effect sizes for schizophrenia loci in major depression (P GSMR = 1.1 × 10
) and for major depression loci in schizophrenia (P GSMR = 1.5 × 10
−11
). These results suggest that the major depression-schizophrenia r g of 0.34 is consistent with partially shared biological pathways being causal for both disorders.
Although it is plausible that diagnostic misclassification/ambiguity (for example, misdiagnosis of MDD as schizoaffective disorder) could contaminate these analyses, levels of misclassification would need to be implausibly high (30% unidirectional, 15% bidirectional) to result in an r g of ~0.3 65 . All MR analyses were repeated after excluding the 23 and Me cohort, and the pattern of the results was the same (Supplementary Table 13 ).
Discussion
The nature of severe depression has been discussed for millennia 66 . This genome-wide association meta-analysis is among the largest ever conducted in psychiatric genetics and provides a body of results that helps refine the fundamental basis of major depression.
In conducting this meta-analysis of major depression, we employed a pragmatic approach by including cohorts that met empirical criteria for sufficient genetic and phenotypic similarity. Our approach was cautious, clinically informed, guided by empirical data, and selective (for example, we did not include cohorts with bipolar disorder (which requires MDD), depressive symptoms, neuroticism, or well-being). Approximately 44% of all major depression cases were assessed using traditional methods (PGC29, GenScot), treatment registers (iPSYCH, GERA; such approaches have been extensively used to elucidate the epidemiology of major depression), or a combination of methods (deCODE, UK Biobank), whereas ~56% of cases were from 23andMe (via self-report) 28 . Multiple lines of genetic evidence supported conducting meta-analysis of these seven cohorts (for example, out-of-sample prediction, sign tests, and genetic correlations).
However, our approach may be controversial to some readers given the unconventional reliance on self-report of major depression. We would reframe the issue: we hypothesize that brief methods of assessing major depression are informative for the genetics of MDD. We present a body of results that is consistent with this hypothesis. Even if unconventional, our hypothesis is testable and falsifiable, and we invite and welcome empirical studies to further support or refute this hypothesis.
Our results lead us to draw some broad conclusions. First, major depression is a brain disorder. Although this is not unexpected, some past models of MDD have had little or no place for heredity or biology. The genetic results best match gene expression patterns in the prefrontal and anterior cingulate cortex, anatomical regions that show differences between MDD cases and controls. The genetic findings implicated neurons (not microglia or astrocytes), and we anticipate more detailed cellular localization when sufficient singlecell and single-nucleus RNA-seq datasets become available 67 . Second, the genetic associations for major depression (as with schizophrenia) 46 tend to occur in genomic regions conserved across a range of placental mammals. Conservation suggests important functional roles. Notably, our analyses did not implicate exons or coding regions.
Third, the results also implicated developmental gene regulatory processes. For instance, the genetic findings pointed at the splicing regulator RBFOX1 (the presence of two independent genetic associations in RBFOX1 strongly suggests that it is the relevant gene). Gene set analyses implicated genes containing binding sites to the protein product of RBFOX1, and this gene set is also significantly enriched for rare exonic variation in autism and schizophrenia 56, 57 . These analyses highlight the potential importance of splicing to generate alternative isoforms; risk for major depression may be mediated not by changes in isolated amino acids but rather by changes in the proportions of isoforms coming from a gene, given that isoforms often have markedly different biological functions 68, 69 . These convergent results provide possible clues to a biological mechanism common to multiple severe psychiatric disorders that merits future research.
Fourth, in the most extensive analysis of the genetic 'connections' of major depression with a wide range of disorders, diseases, and human traits, we found significant positive genetic correlations with measures of body mass and negative genetic correlations with years of education, while showing no evidence of genetic correlation with IQ. MR analysis results are consistent with both BMI and years of education being causal, or correlated with causal, risk factors for major depression, and our results provide hypotheses and motivation for more detailed prospective studies, as currently available data may not provide insight about the fundamental driver or drivers of causality. The underlying mechanisms are likely more complex, as it is difficult to envision how genetic variation in educational attainment or body mass alters risk for MDD without invoking an additional mechanistic component. While the significant MR analyses need further investigations to fully understand, the negative MR results provide important evidence that there is not a direct causal relationship between MDD and subsequent changes in body mass or education years. If such associations are observed in epidemiological or clinical samples, then other factors must drive the association.
Fifth, we found significant positive correlations of major depression with all psychiatric disorders that we evaluated, including disorders prominent in childhood. This pattern of results indicates that the current classification scheme for major psychiatric disorders does not align well with the underlying genetic basis of these disorders. Currently, only schizophrenia has a sufficient number of genome-wide significant loci to conduct MR analysis, but the bidirectionally significant MR results are consistent with a shared biological basis for major depression and schizophrenia. Table 11 ) fall into nine main clusters as described in the text.
The dominant psychiatric nosological systems were principally designed for clinical utility and are based on data that emerge during human interactions (i.e., observable signs and reported symptoms) and not objective measurements of pathophysiology. MDD is frequently comorbid with other psychiatric disorders, and the phenotypic comorbidity has an underlying structure that reflects shared origins (as inferred from factor analyses and twin studies) [70] [71] [72] [73] . Our genetic results add to this knowledge: major depression is not a discrete entity at any level of analysis. Rather, our data strongly suggest the existence of biological processes common to major depression and schizophrenia (and likely other psychiatric disorders).
Finally, as expected, we found that major depression had modest h SNP 2 (8.7%), as it is a complex malady with both genetic and environmental determinants. We found that major depression has a very high genetic correlation with proxy measures that can be briefly assessed. Lifetime major depressive disorder requires a constellation of signs and symptoms whose reliable scoring requires an extended interview with a trained clinician. However, the common variant genetic architecture of lifetime major depression in these seven cohorts (containing many subjects medically treated for MDD) has strong overlap with that of current depressive symptoms in general community samples. Similar relationships of clinically defined ADHD or autism with quantitative genetic variation in the population have been reported 74, 75 . The 'disorder-versus-symptom' relationship has been debated extensively 76 , but our data indicate that the common variant genetic overlap is very high. This finding has important implications.
One implication is for future genetic studies. In a first phase, it should be possible to elucidate the bulk of the common variant genetic architecture of MDD using a cost-effective shortcut-large studies of genotyped individuals who complete online self-report assessments of lifetime MDD (a sample size approaching 1 million MDD cases may be achievable by 2020). Use of online assessment could allow for recording of a broad range of phenotypes including comorbidities and putative environmental exposures, but with the key feature being large samples with consistently assessed measures. In a second phase, with a relatively complete understanding of the genetic basis of major depression, one could then evaluate smaller samples of carefully phenotyped individuals with MDD to understand the clinical importance of the genetic results. Subsequent empirical studies may show that it is possible to stratify MDD cases at first presentation to identify individuals at high risk for recurrence, poor outcome, poor treatment response, or who might subsequently develop a psychiatric disorder requiring alternative pharmacotherapy (for example, schizophrenia or bipolar disorder). This could form a cornerstone of precision medicine in psychiatry.
In summary, this genome-wide association meta-analysis of 135,438 MDD and major depression cases and 344,901 controls identified 44 loci. An extensive set of companion analyses provide insights into the nature of MDD as well as its neurobiology, therapeutic relevance, and genetic and biological interconnections to other psychiatric disorders. Comprehensive elucidation of these features is the primary goal of our genetic studies of MDD. 
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